Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

RegeneRx receives grant to support phase II epidermolysis bullosa trial of TB4

Aug. 16, 2006

AVR-118 accelerates wound healing in pig study

Aug. 10, 2006

Phase IIb study to assess PEP-005 Topical in actinic keratosis

Aug. 7, 2006

Sabarep makes good progress

Aug. 3, 2006

Xolegel approved for seborrheic dermatitis

July 31, 2006

U.K. NICE recommends targeted biological therapies for severe plaque psoriasis

July 31, 2006

Agents for dermatological conditions prepared and tested

July 28, 2006

LL-4218 cleared to begin phase II trials for psoriasis in India

July 28, 2006

Foamix's betamethasone foam shows efficacy and good usability in psoriasis

July 25, 2006

Facial rejuvenation product ICX-RHY completes phase I

July 25, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...